title: Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.
abstract: BACKGROUND
  Neuroendocrine tumors are uncommon tumors that are histopathologically and biologically heterogeneous and include the multiple endocrine neoplasia (MEN) 1 and 2 syndromes. The morbidity of MEN-1 and MEN-2 is often due to the symptomatology of the endocrine hormones produced, and the mortality mainly occurs from hepatic dysfunction incurred by liver metastases. At present, there is essentially no effective cure once the tumor has metastasized to the liver.
  
  
  METHODS
  We present a patient with progressive, metastatic MEN-1 with the classic '3 P's' triad of neuroendocrine tumor of the pancreas, parathyroid adenoma and a pituitary adenoma.
  
  
  RESULTS
  After progression on high-dose Sandostatin LAR (60 mg/month) and multiple surgeries, the patient had a partial response (40% decrease) to a novel regimen of capecitabine and temozolomide (CAPTEM) and progression-free survival of 18 months. He had minor grade 1 toxicities and no grade 2, 3 or 4 toxicities.
  
  
  CONCLUSIONS
  The history and treatment options for MEN-1/2 cancers are reviewed, as well as the data behind our novel regimen, CAPTEM.
  
  
  CONCLUSIONS
  The CAPTEM regimen is a tolerable, safe, easy to administer oral regimen with possible efficacy for MEN-1 tumors.
authors.affiliation: Experimental Therapeutics Program, Division of Medical Oncology, New York Presbyterian-Columbia University Medical Center, New York, N.Y., USA.
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Gulati
authors.forename: Benjamin
authors.initials: B
authors.lastname: Krantz
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Moss
authors.forename: Wendy N
authors.initials: WN
authors.lastname: Moyal
authors.forename: Dawn A
authors.initials: DA
authors.lastname: Tsushima
authors.forename: Kelley B
authors.initials: KB
authors.lastname: Mowatt
authors.forename: Stephen
authors.initials: S
authors.lastname: Schreibman
authors.forename: Robert L
authors.initials: RL
authors.lastname: Fine
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000188:drug therapy*; D018813:Multiple Endocrine Neoplasia Type 2a / Q000188:drug therapy*; D011379:Prognosis; D012196:Review Literature as Topic; D000077204:Temozolomide; D014057:Tomography, X-Ray Computed
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D003606:Dacarbazine; D005472:Fluorouracil; D000077204:Temozolomide